Filter By Category
Archives
Share on -
AMIVANTAMAB
Generic Name: AMIVANTAMAB
ABSTRACT -
Amivantamab is a fully human bispecific monoclonal antibody directed against epidermal growth factor receptor (EGFR) and MET. It is used for selected forms of locally advanced or metastatic non-small cell lung cancer with EGFR mutations, depending on region and regimen. Its mechanisms include blocking EGFR/MET signaling, receptor degradation, and immune-cell-mediated tumor-cell killing.
DOSAGE -
Dosage should be determined only by an oncology specialist.
Intravenous amivantamab dosing is weight-based and regimen-specific; common adult IV schedules include a split first dose followed by weekly doses during initial treatment and then dosing every 2 or 3 weeks depending on the combination regimen.
Subcutaneous amivantamab/hyaluronidase formulations, where approved, follow separate product-specific schedules and safety instructions.
Premedication, infusion or administration monitoring, and dose modifications must follow the current local product label.
SIDE EFFECTS–
Possible side effects may include:
- Infusion-related or administration-related reactions
- Rash, dermatitis acneiform, pruritus, dry skin, or paronychia
- Interstitial lung disease/pneumonitis
- Diarrhoea, nausea, vomiting, or stomatitis
- Fatigue, edema, musculoskeletal pain, or dyspnea
- Ocular toxicity including keratitis or dry eye
- Laboratory abnormalities such as decreased albumin or electrolyte changes
ALLRGIC REACTIONS–
Hypersensitivity or administration-related reactions can occur with amivantamab. Symptoms may include:
- Dyspnea, wheezing, or chest discomfort
- Fever, chills, flushing, or nausea
- Hypotension or tachycardia
- Rash or urticaria
- Anaphylaxis or severe administration reaction
Important: Patients who develop an allergic reaction to Amivantamab should seek immediate medical attention and inform all future healthcare providers of the allergy.
DRUG INTERACTIONS–
Amivantamab may interact with certain medicines or substances. Caution is needed with:
- Combination regimens with lazertinib, carboplatin, or pemetrexed require regimen-specific toxicity monitoring.
- Avoid live vaccines in immunocompromised oncology patients unless oncology guidance supports use.
- Other EGFR/MET-targeted agents or dermatologic toxic medicines may increase overlapping toxicity.
- Patients should report all anticancer therapies, prescription medicines, OTC medicines, and supplements.
Patients should inform healthcare providers about all prescription medicines, over-the-counter medicines, herbal products, and supplements they are using.
PREAUTIONS–
- Confirm EGFR mutation status using an approved test where required.
- Use in experienced oncology centers with emergency management for infusion reactions.
- Monitor for lung symptoms, severe rash, ocular symptoms, venous thromboembolism risk in some combinations, and laboratory abnormalities.
- Advise effective contraception according to label because fetal harm is possible.
WARNINGS –
- Severe infusion/administration reactions can occur, especially early in treatment.
- Interstitial lung disease/pneumonitis can be serious or fatal.
- Severe dermatologic reactions and ocular toxicity require prompt assessment and dose management.
- Keep out of reach of children.
Share on -
. Developed by